Get the Stockscreener App
1.93
6.63%
0.12
After Hours:
1.98
0.05
+2.59%
Sab Biotherapeutics Inc Stock (SABS) Forecast
The Sab Biotherapeutics Inc (SABS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $2.279, representing a +18.08% increase from the current price of $1.93. The highest analyst price target is $2.2678, and the lowest is $2.2902.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month SABS Price Target
Average 2.2536
(+16.76% Upside)
Is Sab Biotherapeutics Inc (SABS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 59.43 | Neutral |
| STOCH(9,6) | 40.41 | Neutral |
| STOCHRSI(14) | 51.05 | Neutral |
| MACD(12,26) | 0.0646 | Sell |
| ADX(14) | 28.59 | Buy |
| William %R | -44.44 | Neutral |
| CCI(14) | 36.78 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.8153
Buy
|
1.8221
Buy
|
| MA20 |
1.7985
Buy
|
1.7763
Buy
|
| MA50 |
1.5787
Buy
|
1.7476
Buy
|
| MA100 |
1.9671
Sell
|
1.9869
Sell
|
| MA200 |
2.5366
Sell
|
2.5132
Sell
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, SABS could be considered a Potential Buy, with 17 technical analysis indicators signaling 7 Buy signals, 5 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on SABS, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 59.43 indicates that SABS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 40.41 indicates that SABS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 51.05 indicates that SABS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 28.59 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 36.78 indicates that SABS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term SABS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Sab Biotherapeutics Inc financial reports and earnings history, Sab Biotherapeutics Inc (SABS) stock could reach $0.6562 by 2030, $18.80 by 2040 and $15.60 by 2050. See the projected annual prices until 2050 of the Sab Biotherapeutics Inc stock below:
- Sab Biotherapeutics Inc (SABS) is expected to reach an average price of $10.03 in 2035, with a high prediction of $10.05 and a low estimate of $10.01. This indicates an $419.53% rise from the last recorded price of $1.93.
- Sab Biotherapeutics Inc (SABS) stock is projected to chart a bullish course in 2040, with an average price target of $18.79, representing an $873.80% surge from its current level. The forecast ranges from a conservative $18.81 to a sky-high $18.80.
- Our analysts predict Sab Biotherapeutics Inc (SABS) to jump 1,370% by 2045, soaring from $28.22 to an average price of $28.37, potentially reaching $27.96. While $28.22 is the low estimate, the potential upside is significant.
- Sab Biotherapeutics Inc (SABS) stock is expected to climb by 2050, reaching an average of $14.91, a $672.77% jump from its current level. However, a wide range of estimates exists, with high and low targets of $15.60 and $14.80, respectively, highlighting the market's uncertainty.
Sab Biotherapeutics Inc Stock (SABS) Year by Year Forecast
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2025
Sab Biotherapeutics Inc Stock (SABS) is expected to reach an average price of $2.3159 in 2025, with a high prediction of $2.7703 and a low estimate of $1.8614. This indicates an +19.99% rise from the last recorded price of $1.93.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $2.2403 | $2.2902 | $2.2678 | +16.08% |
| August, 2025 | $2.5728 | $2.2659 | $2.3128 | +33.31% |
| September, 2025 | $2.4753 | $2.55 | $2.5585 | +28.25% |
| October, 2025 | $2.4403 | $2.4725 | $2.4309 | +26.44% |
| November, 2025 | $2.5192 | $2.4504 | $2.4147 | +30.53% |
| December, 2025 | $2.2786 | $2.5516 | $2.5358 | +18.06% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2026
The predicted value for Sab Biotherapeutics Inc (SABS) in 2026 is set at an average of $3.0814. Estimates vary from a peak of $4.6128 to a trough of $1.5499, indicating an +59.66% surge from the present price of $1.93.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $2.0202 | $2.0966 | $1.9954 | +4.68% |
| February, 2026 | $1.9726 | $2.0092 | $2.0023 | +2.21% |
| March, 2026 | $2.0017 | $1.9907 | $1.9917 | +3.71% |
| April, 2026 | $1.9498 | $1.9486 | $1.9573 | +1.03% |
| May, 2026 | $2.0323 | $1.965 | $1.9111 | +5.30% |
| June, 2026 | $1.9949 | $1.9844 | $1.9749 | +3.36% |
| July, 2026 | $1.614 | $1.9325 | $2.0195 | -16.37% |
| August, 2026 | $1.5452 | $1.5499 | $1.5686 | -19.94% |
| September, 2026 | $1.6032 | $1.5576 | $1.5313 | -16.93% |
| October, 2026 | $3.4338 | $1.6909 | $4.6128 | +77.92% |
| November, 2026 | $3.6713 | $2.4713 | $4.0182 | +90.22% |
| December, 2026 | $2.2031 | $1.9631 | $3.7644 | +14.15% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Sab Biotherapeutics Inc (SABS) is $2.9346, with a high forecast of $5.8691 and a low forecast of $0.000071. This indicates an +52.05% increase from the last price of $1.93.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.6806 | $1.7719 | $4.0863 | +38.89% |
| February, 2027 | $2.1481 | $1.815 | $2.7981 | +11.30% |
| March, 2027 | $0.7887 | $0.4013 | $2.5225 | -59.13% |
| April, 2027 | $1.5437 | $0.0938 | $3.7537 | -20.02% |
| May, 2027 | $0.4113 | $0.000071 | $1.9512 | -78.69% |
| June, 2027 | $2.2676 | $0.8726 | $2.2176 | +17.49% |
| July, 2027 | $2.9927 | $2.9489 | $2.6627 | +55.06% |
| August, 2027 | $5.8477 | $3.0339 | $5.8377 | +202.99% |
| September, 2027 | $4.824 | $4.5115 | $5.599 | +149.95% |
| October, 2027 | $5.599 | $5.2252 | $5.194 | +190.10% |
| November, 2027 | $5.3441 | $5.6066 | $5.4729 | +176.89% |
| December, 2027 | $5.9404 | $5.9404 | $5.8691 | +207.79% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2028
In 2028, Sab Biotherapeutics Inc (SABS) is projected to reach an average price of $5.6607, with a high projection of $6.2865 and a low estimate of $5.0349. This indicates an +193.30% rise from the last price of $1.93.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $6.1354 | $6.0541 | $6.0029 | +217.90% |
| February, 2028 | $6.2214 | $6.0692 | $6.0204 | +222.35% |
| March, 2028 | $6.2768 | $6.3167 | $6.2865 | +225.22% |
| April, 2028 | $6.0818 | $6.0895 | $6.0681 | +215.12% |
| May, 2028 | $5.498 | $5.6853 | $5.9233 | +184.87% |
| June, 2028 | $5.6221 | $5.5718 | $5.5006 | +191.30% |
| July, 2028 | $5.8581 | $5.75 | $5.807 | +203.53% |
| August, 2028 | $5.634 | $5.6543 | $5.6219 | +191.92% |
| September, 2028 | $5.5594 | $5.5794 | $5.5457 | +188.05% |
| October, 2028 | $5.5966 | $5.5407 | $5.5232 | +189.98% |
| November, 2028 | $5.0525 | $5.3008 | $5.5686 | +161.79% |
| December, 2028 | $4.9558 | $5.0349 | $4.9346 | +156.78% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2029
The 2029 price forecast for Sab Biotherapeutics Inc Stock (SABS) is $2.4811 on average, with a high prediction of $4.8772 and a low estimate of $0.085. This represents an +28.55% increase from the previous price of $1.93.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $4.8821 | $4.8655 | $4.8772 | +152.96% |
| February, 2029 | $4.7271 | $4.7371 | $4.8234 | +144.93% |
| March, 2029 | $4.6929 | $4.7104 | $4.6816 | +143.15% |
| April, 2029 | $4.6138 | $4.658 | $4.621 | +139.06% |
| May, 2029 | $4.5435 | $4.6155 | $4.65 | +135.41% |
| June, 2029 | $4.0886 | $4.1204 | $4.4248 | +111.85% |
| July, 2029 | $4.0736 | $4.0798 | $4.0598 | +111.07% |
| August, 2029 | $4.1289 | $4.0157 | $4.0346 | +113.93% |
| September, 2029 | $1.2851 | $0.5851 | $4.049 | -33.41% |
| October, 2029 | $0.9188 | $0.1426 | $1.4788 | -52.39% |
| November, 2029 | $0.9038 | $0.085 | $0.9574 | -53.17% |
| December, 2029 | $0.00127 | $0.0913 | $1.8725 | -99.93% |
Sab Biotherapeutics Inc Stock (SABS) Price Forecast for 2030
Sab Biotherapeutics Inc Stock (SABS) is expected to reach an average price of $4.8839 in 2030, with a high forecast of $9.7615 and a low forecast of $0.00621. This signifies an +153.05% surge from the last price of $1.93.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $0.3312 | $0.00621 | $0.6562 | -82.84% |
| February, 2030 | $2.0907 | $3.3838 | $4.03 | +8.32% |
| March, 2030 | $3.6382 | $2.8276 | $2.2613 | +88.51% |
| April, 2030 | $5.4958 | $4.1251 | $4.3758 | +184.75% |
| May, 2030 | $6.4102 | $6.7927 | $6.2564 | +232.14% |
| June, 2030 | $9.3378 | $7.0009 | $6.9478 | +383.82% |
| July, 2030 | $8.1822 | $8.3922 | $9.7615 | +323.95% |
| August, 2030 | $8.9698 | $9.0629 | $8.616 | +364.75% |
| September, 2030 | $9.3173 | $9.1766 | $9.1961 | +382.76% |
| October, 2030 | $9.5818 | $9.3436 | $9.4519 | +396.46% |
| November, 2030 | $9.7393 | $9.6055 | $9.6393 | +404.63% |
| December, 2030 | $9.6169 | $9.6762 | $9.6062 | +398.28% |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):